News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Orthocell.
RELATED STOCKHEAD STORIES
Health & Biotech
US FDA approval is on the agenda for these 5 ASX small caps
Experts
Scopo’s health powerplays: The cash caboose keeps rolling on
Health & Biotech
Health: Amplia really gives a FAK about cancer as phase 1 trial still on track
Experts
Scopo’s health powerplays: Clinical trials are back
Health & Biotech
Health: PharmAust proves its doggie cancer drug works; shares up 40pc
Health & Biotech
Scale-up secret sauce: These are the ingredients for medtech growth
Health & Biotech
Medtech needs more than a TGA tick to hit the big $$$
Health & Biotech
Dr Boreham’s Crucible: The small cap biotechs trying to make a buck from coronavirus
News
The traps and the opportunities: How to play equity markets in a global pandemic
Health & Biotech
WA biotechs are booming; now government wants to make the state a life sciences hub
Health & Biotech
Health: Alterity gets orphan status for its MSA drug
News
Short and Caught: The ASX stocks investors are shorting right now
News
The 10 ASX stocks that more than tripled in a single day in 2019
Health & Biotech
Health: Is this the big news from Germany Pharmaxis was waiting for?
Health & Biotech
Biotech exec pay — are they delivering returns that equal their pay packets?
Health & Biotech
Health: Orthocell believes CelGro can help repair ACL injuries
Health & Biotech